K562 chronic myeloid leukemia cells as a dual β3-expressing functional cell line model to investigate the effects of combined αIIbβ3 and αvβ3 antagonism
Elsharif, Amal A.M. Patterson, Laurence H.
Elsharif, Amal A.M.
Patterson, Laurence H.
Publication Date
2025-07
End of Embargo
Supervisor
Rights
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Peer-Reviewed
Yes
Open Access status
openAccess
Accepted for publication
2025-07-03
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Several of the integrin family of cell adhesion receptors have been popular targets for the development of anticancer agents, but with little clinical success to date. Cancer cells usually express multiple redundant integrins; one hypothesis for the lack of efficacy of current antagonists is their high selectivity for a single integrin. To address this, we developed a functional dual-β3-expressing cell model to investigate the effects of combined αIIbβ3/αvβ3 antagonism. We established that treating K562 chronic myeloid leukemia cells with 0.04 μM phorbol 12-myristate 13-acetate (PMA) for 40 h significantly upregulates functional αIIbβ3 and αvβ3 integrins. This optimized method provides a reliable platform for adhesion and detachment assays, enabling the characterization of dual integrin targeting strategies. Using this model, we demonstrate that combining αIIbβ3 and αvβ3 antagonists (GR144053 and cRGDfV) synergistically enhances inhibition of cell adhesion and promotes cell detachment compared to single-agent treatments. Our findings establish a reproducible approach for studying dual β3 integrin targeting, which can be used to investigate potential strategies for overcoming integrin redundancy in cancer therapeutics.
Version
Published version
Citation
Elsharif AA, Patterson LH, Shnyder SD et al (2025) K562 chronic myeloid leukemia cells as a dual β3-expressing functional cell line model to investigate the effects of combined αIIbβ3 and αvβ3 antagonism. Methods And Protocols. 8(4): 73.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article